Nereus initiates phase 1b trial of NPI-2358 in NSCLC patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 4
Volume 17
Issue 4

Nereus Pharmaceuticals, Inc. has begun enrolling patients in an open-label phase 1b study evaluating its vascular disrupting agent NPI-2358 in combination with docetaxel (Taxotere) in patients with non-small-cell lung cancer who previously failed at least one chemotherapy regimen.

SAN DIEGO-Nereus Pharmaceuticals, Inc. has begun enrolling patients in an open-label phase 1b study evaluating its vascular disrupting agent NPI-2358 in combination with docetaxel (Taxotere) in patients with non-small-cell lung cancer who previously failed at least one chemotherapy regimen. NPI-2358 selectively attacks existing tumor blood vessels leading to hemorrhagic tumor necrosis without affecting normal vasculature and it has a direct apoptotic effect on tumor cells.

Articles in this issue
Proton therapy training offered
Editor of Blood reviews a very bloody movie
Artists take note: Oncology on Canvas accepting entries
PET affects treatment in over one-third of cancer cases
Expanded use of Axxent approved
Gardasil supplemental application gets priority review designation
Optical tomo/US monitors adjuvant chemo response
GIST patients resistant to imatinib/sunitinib respond to sorafenib
Sunitinib plus a taxane active in advanced breast cancer
Stanford V yields excellent outcomes in bulky, advanced HL
Monica Morrow joins Memorial Sloan-Kettering Cancer Center
Nereus initiates phase 1b trial of NPI-2358 in NSCLC patients
LHRH agonist use declines after reimbursement cuts
Palliative care helps pediatric pts at end of life
New colon screening guideline includes CT colonography

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Related Content
A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

Tislelizumab Significantly Boosts Survival in Lung Cancer Trials

Russ Conroy
April 23rd 2025
Article

A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC

Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC

Tim Cortese
April 23rd 2025
Article

The phase 3 HARMONi-6 trial found invonescimab plus chemotherapy improved PFS vs tislelizumab plus chemotherapy in squamous NSCLC.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

Tim Cortese
April 20th 2025
Article

A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.

End-of-life demands card game and mindfulness-based cancer recovery program use may enhance the quality of life for patients with lung cancer.

Mindfulness/Activity Program May Ease Anxiety Over Death from Lung Cancer

Roman Fabbricatore
April 19th 2025
Article

End-of-life demands card game and mindfulness-based cancer recovery program use may enhance the quality of life for patients with lung cancer.